Could a single infusion of 'Trainer' cells let kidney patients ditch daily pills?
NCT ID NCT06777719
First seen May 10, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This early-stage trial tests a new cell therapy called Eight Treg in 9 people receiving a kidney from a living donor. The therapy uses the patient's own immune cells, grown in a lab, to help the body accept the new kidney without strong anti-rejection drugs. The main goal is to check safety, but researchers hope it may one day reduce the need for lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nantes
RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD8+ regulatory T cells (Eight Treg)
What this could lead to
If successful, this could reduce the need for lifelong immunosuppressive drugs after kidney transplant, lowering infection and cancer risks.
What could go wrong
This is a very early Phase 1 trial with only 9 people, focused on safety. The therapy may not work or could cause unexpected side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.